In May 2025, Aon released the first phase of a US study of GLP-1 medications for
diabetes and weight management.
Across the global technology sector, employers are facing unprecedented complexity—distributed teams, dynamic regulations, and rapidly evolving expectations around pay, benefits, and wellbeing. Aon’s role is to help tech companies cut through this complexity, using data and global insight so leaders can make confident decisions that support their people and their growth.
Now, in 2026, Aon has released the second phase of research, expanding the study to
include a larger, nationally representative sample of GLP-1 users.
Key Findings:
- Diabetes-related findings: Over a 30-month period, users of GLP-1s for
diabetes experienced a slower increase in medical cost growth compared to non-
users. The clinical benefits continue to be observed in the second analysis. - Weight loss-related findings: Individuals using GLP-1s for 18 months show the
same pattern of reduced medical cost growth. - Adherence: Adherence is a critical driver of value. GLP-1 users who maintain at
least 80% adherence to therapy see greater cost reductions than those with
lower adherence. - Women’s health: Female GLP-1 users are more likely to see reductions in
hospitalizations for alcohol abuse, bariatric surgery and pancreatic disorders
compared to males. Women GLP-1 users were also observed to have lower
incidence of ovarian cancer, breast cancer and osteoporosis than female non-
users.
Click here for the full article.